{"content":"<li class=\"n-box-item date-title\" data-end=\"1499745599\" data-start=\"1499659200\" data-txt=\"Monday, December 23, 2019\">Monday, July 10, 2017</li><li class=\"n-box-item sa-box-item\" data-id=\"3277811\" data-ts=\"1499727568\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/TV\" target=\"_blank\">TV</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3277811-televisa-moves-up-4_4-ahead-of-earnings-report\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Televisa moves up 4.4% ahead of earnings report</a></h4><ul>   <li>Grupo Televisa (NYSE:<a href='https://seekingalpha.com/symbol/TV' title='Grupo Televisa, S.A.'>TV</a>) moved <font color='green'>up 4.4%</font> today on heavy volume ahead of earnings to be reported tonight, and has seen some profit-taking in relatively thinner trading after the closing bell.</li>    <li>Shares in the broadcaster moved at a volume of 2.076M on NYSE, about 25% higher than average. After hours, meanwhile, shares fell as much as <font color='red'>4.9% lower</font> before the past few trades came in down just 0.9%.</li>    <li>For the quarter ended in June, consensus expectations are for the company to post EPS of 2.34 pesos on revenue of 23.56B pesos.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3277811\" data-linked=\"Televisa moves up 4.4% ahead of earnings report\" data-tweet=\"$TV - Televisa moves up 4.4% ahead of earnings report https://seekingalpha.com/news/3277811-televisa-moves-up-4_4-ahead-of-earnings-report?source=tweet\" data-url=\"https://seekingalpha.com/news/3277811-televisa-moves-up-4_4-ahead-of-earnings-report\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  6:59 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3277809\" data-ts=\"1499724419\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/RCII\" target=\"_blank\">RCII</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3277809-rent-centerplus-26-on-report-of-15-share-buyout-bid\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Rent-A-Center +26% on report of $15/share buyout bid</a></h4><ul>     <li>Rent-A-Center (NASDAQ:<a href='https://seekingalpha.com/symbol/RCII' title='Rent-A-Center Inc.'>RCII</a>)&nbsp;<font color='green'>+26.1%</font> AH following a Reuters report that Vintage Capital has <a href=\"http://www.reuters.com/article/us-rent-a-center-m-a-vintage-exclusive-idUSKBN19V2QE\" target=\"_blank\">offered to buy the company for $15/share</a>, or ~$800M.</li>     <li>The P-E firm made the offer in a June 20 letter to JPMorgan Chase, RCII's investment bank, according to the report.</li>     <li>Reuters also says RCII believes Vintage Capital's proposal \"significantly undervalues the company\" and its strategic plan.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3277809\" data-linked=\"Rent-A-Center +26% on report of $15/share buyout bid\" data-tweet=\"$RCII - Rent-A-Center +26% on report of $15/share buyout bid https://seekingalpha.com/news/3277809-rent-centerplus-26-on-report-of-15-share-buyout-bid?source=tweet\" data-url=\"https://seekingalpha.com/news/3277809-rent-centerplus-26-on-report-of-15-share-buyout-bid\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  6:06 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>11&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3277805\" data-ts=\"1499722670\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3277805-after-hours-gainers-losers\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">After Hours Gainers / Losers</a></h4><ul>     <li><b>Top gainers:</b> <a href='https://seekingalpha.com/symbol/ARNA' title='Arena Pharmaceuticals, Inc.'>ARNA</a> <font color='green'>+48.0%</font>. <a href='https://seekingalpha.com/symbol/OCUL' title='Ocular Therapeutix'>OCUL</a> <font color='green'>+13.8%</font>. <a href='https://seekingalpha.com/symbol/NTLA' title='Intellia Therapeutics'>NTLA</a> <font color='green'>+2.8%</font>. <a href='https://seekingalpha.com/symbol/VSTO' title='Vista Outdoor'>VSTO</a> <font color='green'>+2.4%</font>. <a href='https://seekingalpha.com/symbol/SPWH' title='Sportsman&#39;s Warehouse Holdings, Inc.'>SPWH</a> <font color='green'>+2.2%</font>.</li><li><b>Top losers:</b> <a href='https://seekingalpha.com/symbol/VOXX' title='VOXX International Corp.'>VOXX</a> <font color='red'>-24.3%</font>. <a href='https://seekingalpha.com/symbol/CUDA' title='Barracuda Networks, Inc'>CUDA</a> <font color='red'>-5.0%</font>. <a href='https://seekingalpha.com/symbol/CTXS' title='Citrix Systems, Inc.'>CTXS</a> <font color='red'>-3.7%</font>. <a href='https://seekingalpha.com/symbol/DAVE' title='Famous Dave&#39;s of America, Inc.'>DAVE</a> <font color='red'>-3.2%</font>. <a href='https://seekingalpha.com/symbol/TV' title='Grupo Televisa, S.A.'>TV</a> <font color='red'>-2.6%</font>.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3277805\" data-linked=\"After Hours Gainers / Losers\" data-tweet=\"$ARNA $OCUL $NTLA - After Hours Gainers / Losers https://seekingalpha.com/news/3277805-after-hours-gainers-losers?source=tweet\" data-url=\"https://seekingalpha.com/news/3277805-after-hours-gainers-losers\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  5:37 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>11&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3277799\" data-ts=\"1499721117\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/ALEX\" target=\"_blank\">ALEX</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3277799-alexander-baldwin-taps-mead-cfo-adds-realty-income-vet-to-board\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Alexander &amp; Baldwin taps Mead as CFO, adds Realty Income vet to board</a></h4><ul>   <li>Alexander &amp; Baldwin (<a href=\"http://seekingalpha.com/symbol/ALEX\" target=\"_blank\">ALEX</a> <font color='red'>-1.6%</font>) has named James Mead its <a href=\"https://seekingalpha.com/pr/16882329-alexander-and-baldwin-names-experienced-reit-executive-james-mead-new-chief-financial-officer\" target=\"_blank\">new chief financial officer</a>, effective immediately.</li>    <li>Mead succeeds Paul Ito, who's remaining as senior VP, finance and treasurer for a transition through year's end. Mead was most recently CFO for SL Green Realty.</li>    <li>The company also <a href=\"https://seekingalpha.com/pr/16882330-experienced-reit-executive-thomas-lewis-named-alexander-and-baldwin-board-directors\" target=\"_blank\">added Thomas Lewis</a>, former CEO of Realty Income, to its board. After taking Realty Income public in the '90s, Lewis retired in 2013, and also serves on the board of Sunstone Hotel Investors.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3277799\" data-linked=\"Alexander &amp; Baldwin taps Mead as CFO, adds Realty Income vet to board\" data-tweet=\"$ALEX - Alexander &amp; Baldwin taps Mead as CFO, adds Realty Income vet to board https://seekingalpha.com/news/3277799-alexander-baldwin-taps-mead-cfo-adds-realty-income-vet-to-board?source=tweet\" data-url=\"https://seekingalpha.com/news/3277799-alexander-baldwin-taps-mead-cfo-adds-realty-income-vet-to-board\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  5:11 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>1&nbsp;<span class='comments-number'>Comment</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3277797\" data-ts=\"1499720536\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/VSTO\" target=\"_blank\">VSTO</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3277797-vista-outdoors-chairman-ceo-deyoung-retires\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Vista Outdoors Chairman/CEO DeYoung retires</a></h4><ul><li>Vista Outdoor (NYSE:<a href='https://seekingalpha.com/symbol/VSTO' title='Vista Outdoor'>VSTO</a>) <font color='green'>+3.9%</font>&nbsp;AH after saying CEO Mark DeYoung is <a href=\"https://seekingalpha.com/pr/16882269-vista-outdoor-announces-leadership-transition\" target=\"_blank\">retiring</a> from the company and the board, effective immediately.</li><li>Lead independent director Michael Callahan will become interim Chairman and CEO while the board pursues a permanent CEO.</li><li>DeYoung was Chairman and CEO since 2015 after serving for five years as CEO and President of Orbital ATK - formerly Alliant Techsystems - capping 30 years at that company.</li></ul><div class=\"tiny-share-widget\" data-id=\"3277797\" data-linked=\"Vista Outdoors Chairman/CEO DeYoung retires\" data-tweet=\"$VSTO - Vista Outdoors Chairman/CEO DeYoung retires https://seekingalpha.com/news/3277797-vista-outdoors-chairman-ceo-deyoung-retires?source=tweet\" data-url=\"https://seekingalpha.com/news/3277797-vista-outdoors-chairman-ceo-deyoung-retires\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  5:02 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3277795\" data-ts=\"1499720095\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/OCUL\" target=\"_blank\">OCUL</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3277795-ocular-submits-amendment-to-dextenza-nda-for-equipment-change-closes-out-form-483-issues-fda\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Ocular submits amendment to Dextenza NDA for equipment change, closes out Form 483 issues; FDA action date October 19; shares ahead 8% after hours</a></h4><ul><li>Ocular Therapeutix (NASDAQ:<a href='https://seekingalpha.com/symbol/OCUL' title='Ocular Therapeutix'>OCUL</a>) is up&nbsp;<font color='green'>8%</font>&nbsp;after hours on increased volume in response to its <a href=\"https://seekingalpha.com/pr/16882239-ocular-therapeutix-submits-amendment-potentially-extend-review-dextenza-new-drug-application\" target=\"_blank\">announcement </a>that its has addressed all Form 483 observations that it received in May after an FDA inspection of its manufacturing operations supporting DEXTENZA (dexamethasone insert).</li><li>The company has filed an amendment to its NDA resubmission pertaining to a modification of manufacturing equipment. It will also submit data on a new commercial batch to demonstrate that the modification, in addition to other changes, has addressed the issues related to particulate matter.</li><li>The amendment represents a material change to the NDA filing so the FDA's action date will be extended 90 days to October 19.</li></ul><div class=\"tiny-share-widget\" data-id=\"3277795\" data-linked=\"Ocular submits amendment to Dextenza NDA for equipment change, closes out Form 483 issues; FDA action date October 19; shares ahead 8% after hours\" data-tweet=\"$OCUL - Ocular submits amendment to Dextenza NDA for equipment change, closes out Form 483 issues; FDA action date October 19; shares ahead 8% after hours https://seekingalpha.com/news/3277795-ocular-submits-amendment-to-dextenza-nda-for-equipment-change-closes-out-form-483-issues-fda?source=tweet\" data-url=\"https://seekingalpha.com/news/3277795-ocular-submits-amendment-to-dextenza-nda-for-equipment-change-closes-out-form-483-issues-fda\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  4:54 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>30&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3277792\" data-ts=\"1499719779\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/SSP\" target=\"_blank\">SSP</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3277792-scripps-sets-ceo-transition-for-aug-8\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Scripps sets CEO transition for Aug. 8</a></h4><ul>    <li>Adam Symson is set to <a href=\"https://seekingalpha.com/pr/16882293-scripps-names-symson-president-ceo-boehne-retire-continue-chairman-board\" target=\"_blank\">take over as president and CEO</a> of E.W. Scripps (<a href=\"http://seekingalpha.com/symbol/SSP\" target=\"_blank\">SSP</a> <font color='green'>+2.1%</font>) on Aug. 8.</li>    <li>He's succeeding Rich Boehne, who continues as the company's chairman (a role he took on in 2013).</li>    <li>Symson had been named chief operating officer in November after a variety of roles since joining the company in 2002. He took over digital operations in 2011.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3277792\" data-linked=\"Scripps sets CEO transition for Aug. 8\" data-tweet=\"$SSP - Scripps sets CEO transition for Aug. 8 https://seekingalpha.com/news/3277792-scripps-sets-ceo-transition-for-aug-8?source=tweet\" data-url=\"https://seekingalpha.com/news/3277792-scripps-sets-ceo-transition-for-aug-8\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  4:49 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3277790\" data-ts=\"1499718917\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/EYPT\" target=\"_blank\">EYPT</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3277790-psivida-amends-agreement-alimera-grants-emea-rights-to-durasert-new-indication-for-iluvien\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">pSivida amends agreement with Alimera, grants EMEA rights to Durasert, new indication for Iluvien planned; shares ahead 2% after hours</a></h4><ul><li>Nano cap pSivida (PSDV) is up&nbsp;<font color='green'>2%</font>&nbsp;after hours on average volume on the heels of its <a href=\"https://seekingalpha.com/pr/16882183-psivida-licenses-emea-rights-durasert-three-year-treatment-posterior-segment-uveitis\" target=\"_blank\">announcement</a> that it has amended its license and collaboration agreement with Alimera Sciences (NASDAQ:<a href='https://seekingalpha.com/symbol/ALIM' title='Alimera Sciences, Inc.'>ALIM</a>).</li><li>Under the terms of the new deal, Alimera obtains the rights to Durasert for the treatment of posterior segment uveitis &#40;PSU&#41; in Europe, the Middle East and Africa &#40;EMEA&#41; (Alimera also intends to pursue a PSU indication for ILUVIEN in EMEA). Profit-sharing for the global ILUVIEN diabetic macular edema &#40;DME&#41; indication will be converted to the same tiered sales-based royalty scheme as PSU effective July 1. Royalties start at 2% and will rise to 8% when ILUVIEN sales exceed $75M in any calendar year. The accumulated net ILUVIEN losses will be capped at $25M, of which $10M is canceled in exchange for the PSU rights. An additional $5M will be canceled if certain milestones are achieved. The remaining $10M can be partially offset against sales-based royalties over time.</li><li>pSivida will withdraw its European marketing application and Orphan Drug designation for PSU transferring the responsibility to Alimera.</li></ul><div class=\"tiny-share-widget\" data-id=\"3277790\" data-linked=\"pSivida amends agreement with Alimera, grants EMEA rights to Durasert, new indication for Iluvien planned; shares ahead 2% after hours\" data-tweet=\"$EYPT $EYPT $ALIM - pSivida amends agreement with Alimera, grants EMEA rights to Durasert, new indication for Iluvien planned; shares ahead 2% after hours https://seekingalpha.com/news/3277790-psivida-amends-agreement-alimera-grants-emea-rights-to-durasert-new-indication-for-iluvien?source=tweet\" data-url=\"https://seekingalpha.com/news/3277790-psivida-amends-agreement-alimera-grants-emea-rights-to-durasert-new-indication-for-iluvien\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  4:35 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>18&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3277787\" data-ts=\"1499718109\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/SHLO\" target=\"_blank\">SHLO</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3277787-shiloh-industries-to-launch-5m-share-offering\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Shiloh Industries to launch 5M-share offering</a></h4><ul><li>Shiloh Industries (NASDAQ:<a href='https://seekingalpha.com/symbol/SHLO' title='Shiloh Industries, Inc.'>SHLO</a>) <font color='red'>-2.9%</font>&nbsp;AH after announcing a <a href=\"https://seekingalpha.com/pr/16882182-shiloh-industries-inc-announces-common-stock-offering\" target=\"_blank\">public offering</a> of 5M common shares, with an underwriters option to purchase up to an additional 750K shares.</li><li>SHLO says it plans to use the proceeds to repay borrowings  under its revolving credit facility.</li></ul><div class=\"tiny-share-widget\" data-id=\"3277787\" data-linked=\"Shiloh Industries to launch 5M-share offering\" data-tweet=\"$SHLO - Shiloh Industries to launch 5M-share offering https://seekingalpha.com/news/3277787-shiloh-industries-to-launch-5m-share-offering?source=tweet\" data-url=\"https://seekingalpha.com/news/3277787-shiloh-industries-to-launch-5m-share-offering\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  4:21 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3277786\" data-ts=\"1499717988\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/CUDA\" target=\"_blank\">CUDA</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3277786-barracuda-networksminus-3_5-earnings-flatten\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Barracuda Networks -3.5% as earnings flatten</a></h4><ul>   <li>Barracuda Networks (NYSE:<a href='https://seekingalpha.com/symbol/CUDA' title='Barracuda Networks, Inc'>CUDA</a>) has <font color='red'>slipped 3.5%</font> after hours following <a href=\"https://seekingalpha.com/news/3277781-barracuda-networks-eps-line-beats-revenue\" target=\"_blank\">Q1 earnings</a> where net income dipped and revenues beat expectations.</li>    <li>GAAP net income fell slightly to $2.7M; non-GAAP income (which excludes stock-based compensation, income tax benefits, amortization and other income as well acquisition charges) was $10M.</li>    <li>Active subscribers exceeded 335,000 as of May 31 (growth of about 17%). Renewal rate was 90% on a dollar basis in constant currency (93% on annualized basis).</li>    <li>While revenues were up 9%, gross billings rose 7.1% to $105.2M. Billing for core products were up 20% to $67.1M.</li>    <li>Revenue breakout: Subscription revenue, $73.9M (up 13%); Appliance revenue, $20.3M (down 4.7%).</li>    <li><a href=\"https://investors.barracuda.com/\" target=\"_blank\">Conference call</a> to come at 4:30 p.m. ET.</li>    <li><a href=\"https://seekingalpha.com/pr/16882191-barracuda-reports-first-quarter-fiscal-2018-results\" target=\"_blank\">Press Release</a></li> </ul><div class=\"tiny-share-widget\" data-id=\"3277786\" data-linked=\"Barracuda Networks -3.5% as earnings flatten\" data-tweet=\"$CUDA - Barracuda Networks -3.5% as earnings flatten https://seekingalpha.com/news/3277786-barracuda-networksminus-3_5-earnings-flatten?source=tweet\" data-url=\"https://seekingalpha.com/news/3277786-barracuda-networksminus-3_5-earnings-flatten\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  4:19 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>2&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3277784\" data-ts=\"1499717642\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/ARNA\" target=\"_blank\">ARNA</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3277784-arena-pharmas-ralinepag-successful-in-mid-stage-pah-study-shares-up-27-after-hours\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Arena Pharma&#39;s ralinepag successful in mid-stage PAH study; shares up 27% after hours</a></h4><ul><li>Arena Pharmaceuticals (NASDAQ:<a href='https://seekingalpha.com/symbol/ARNA' title='Arena Pharmaceuticals, Inc.'>ARNA</a>) jumps&nbsp;<font color='green'>27%</font>&nbsp;after hours on increased volume on the heels of its <a href=\"https://seekingalpha.com/pr/16882173-arena-pharmaceuticals-reports-positive-topline-phase-2-results-ralinepag-patients-pulmonary\" target=\"_blank\">announcement </a>of positive results from a Phase 2 clinical trial assessing ralinepag for the treatment of pulmonary arterial hypertension &#40;PAH&#41;. The 61-subject study demonstrated a statistically valid treatment effect compared to placebo as measured by pulmonary vascular resistance &#40;PVR&#41;, a measure of resistance offered by systemic circulation (p=0.02).</li><li>The company plans to advance ralinepag into Phase 3 development as soon as feasible.</li><li>Ralinepag is an orally administered <a href=\"https://en.wikipedia.org/wiki/Prostacyclin_receptor\" target=\"_blank\">prostacyclin receptor</a> agonist. The prostacyclin receptor is a powerful vasodilator.</li><li>Management will host a conference call at 4:30 pm ET to discuss the results.</li></ul><div class=\"tiny-share-widget\" data-id=\"3277784\" data-linked=\"Arena Pharma&#39;s ralinepag successful in mid-stage PAH study; shares up 27% after hours\" data-tweet=\"$ARNA - Arena Pharma&#39;s ralinepag successful in mid-stage PAH study; shares up 27% after hours https://seekingalpha.com/news/3277784-arena-pharmas-ralinepag-successful-in-mid-stage-pah-study-shares-up-27-after-hours?source=tweet\" data-url=\"https://seekingalpha.com/news/3277784-arena-pharmas-ralinepag-successful-in-mid-stage-pah-study-shares-up-27-after-hours\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  4:14 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>46&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3277781\" data-ts=\"1499717043\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/CUDA\" target=\"_blank\">CUDA</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3277781-barracuda-networks-eps-in-line-beats-on-revenue\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Barracuda Networks EPS in-line, beats on revenue</a></h4><ul><li>Barracuda Networks (NYSE:<a href='https://seekingalpha.com/symbol/CUDA' title='Barracuda Networks, Inc'>CUDA</a>): Q1 EPS of $0.18 in-line.</li><li>Revenue of $94.18M (+8.7% Y/Y) <font color='green'>beats by $3.03M</font>.</li><li>Shares <font color='green'>+1.33%</font>.</li><li><a href='https://seekingalpha.com/pr/16882191-barracuda-reports-first-quarter-fiscal-2018-results'>Press Release</a></li></ul><div class=\"tiny-share-widget\" data-id=\"3277781\" data-linked=\"Barracuda Networks EPS in-line, beats on revenue\" data-tweet=\"$CUDA - Barracuda Networks EPS in-line, beats on revenue https://seekingalpha.com/news/3277781-barracuda-networks-eps-in-line-beats-on-revenue?source=tweet\" data-url=\"https://seekingalpha.com/news/3277781-barracuda-networks-eps-in-line-beats-on-revenue\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  4:04 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>6&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3277780\" data-ts=\"1499716721\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/CF\" target=\"_blank\">CF</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3277780-fertilizer-stocks-jump-corn-prices-hit-highest-since-june-2016\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Fertilizer stocks jump as corn prices hit highest since June 2016</a></h4><ul>     <li><a href=\"http://www.marketwatch.com/story/fertilizer-stocks-surge-to-lead-sp-500-gainers-as-corn-prices-jump-to-13-month-high-2017-07-10\" target=\"_blank\">Fertilizer shares enjoy sharp gains</a> today, as a spike in prices for corn, which is used to develop fertilizer, helps support gains, MarketWatch reports.</li>     <li>Corn prices surged more than 2% to settle above $4/bushel for the first time in 13 months amid concerns over supply in the face of a <a href=\"https://www.wsj.com/articles/traders-gobble-up-wheat-amid-great-plains-drought-1499694938\" target=\"_blank\">drought and rising temperatures in the Great Plains</a>; also, wheat futures have skyrocketed 40% in a little over a month.</li>     <li>CF&nbsp;Industries (<a href='https://seekingalpha.com/symbol/CF' title='CF Industries Holdings, Inc.'>CF</a> <font color='green'>+6.5%</font>) and Mosaic (<a href='https://seekingalpha.com/symbol/MOS' title='The Mosaic Company'>MOS</a> <font color='green'>+5.3%</font>) jump to multi-month highs and rank among today's top gainers on the S&amp;P 500; Potash Corp. (POT <font color='green'>+5.2%</font>) and Agrium (AGU <font color='green'>+5.5%</font>) both were <a href=\"https://www.streetinsider.com/Upgrades/Scotiabank+Upgrades+Potash+Corp.+%28POT%29+to+Sector+Outperform/13083313.html\" target=\"_blank\">upgraded</a> to Outperform from Sector Perform at Scotiabank.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3277780\" data-linked=\"Fertilizer stocks jump as corn prices hit highest since June 2016\" data-tweet=\"$CF $CF $MOS - Fertilizer stocks jump as corn prices hit highest since June 2016 https://seekingalpha.com/news/3277780-fertilizer-stocks-jump-corn-prices-hit-highest-since-june-2016?source=tweet\" data-url=\"https://seekingalpha.com/news/3277780-fertilizer-stocks-jump-corn-prices-hit-highest-since-june-2016\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  3:58 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>15&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3277776\" data-ts=\"1499716534\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/AGEN\" target=\"_blank\">AGEN</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3277776-agenus-breaks-out-of-brief-consolidation-after-glaxo-shingles-vaccine-data-stoked-up-move\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Agenus breaks out of brief consolidation after Glaxo shingles vaccine data-stoked up move; shares ahead 9%</a></h4><ul><li>Agenus (<a href='https://seekingalpha.com/symbol/AGEN' title='Agenus'>AGEN</a> <font color='green'>+9.2%</font>) heads north on more than double normal volume, breaking out of a short consolidation after shares jumped several weeks ago on positive late-stage data on GlaxoSmithKline's Shingrix shingle vaccine.</li><li>Shingrix contains Agenus' QS-21 adjuvant Stimulon. Glaxo's marketing applications in the U.S, Europe and Japan are currently under review.</li><li>Previously: <a href=\"https://seekingalpha.com/news/3274778-glaxos-shingles-vaccine-triggers-immune-response-elderly-patients-previously-treated-mercks\" target=\"_blank\">Glaxo's shingles vaccine triggers immune response in elderly patients previously treated with Merck's Zostavax in late-stage study</a> (June 21)</li></ul><div class=\"tiny-share-widget\" data-id=\"3277776\" data-linked=\"Agenus breaks out of brief consolidation after Glaxo shingles vaccine data-stoked up move; shares ahead 9%\" data-tweet=\"$AGEN - Agenus breaks out of brief consolidation after Glaxo shingles vaccine data-stoked up move; shares ahead 9% https://seekingalpha.com/news/3277776-agenus-breaks-out-of-brief-consolidation-after-glaxo-shingles-vaccine-data-stoked-up-move?source=tweet\" data-url=\"https://seekingalpha.com/news/3277776-agenus-breaks-out-of-brief-consolidation-after-glaxo-shingles-vaccine-data-stoked-up-move\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  3:55 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>10&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3277773\" data-ts=\"1499715676\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/GOLD\" target=\"_blank\">GOLD</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3277773-zaldivar-copper-mine-workers-in-chile-approve-strike\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Zaldivar copper mine workers in Chile approve strike</a></h4><ul>     <li>Workers at the Zaldivar copper mine in Chile, owned by Barrick Gold (ABX <font color='green'>+3.1%</font>) and Antofagasta (<a href='https://seekingalpha.com/symbol/ANFGF' title='Antofagasta plc'>OTC:ANFGF</a>), have voted to <a href=\"http://www.reuters.com/article/us-antofagasta-strike-zaldivar-idUSKBN19V2F4\" target=\"_blank\">approve a strike</a> after labor talks failed, a union leader tells Reuters.</li>     <li>Zaldivar's workers will not walk off immediately, since Chilean law calls for a government mediation period that will last at least five days before workers are legally permitted to strike.</li>     <li>Earlier this year, a strike at BHP's Escondida copper mine in Chile - the world's largest - sent copper prices soaring on supply concerns.</li><li>ETFs: <a href='https://seekingalpha.com/symbol/JJC' title='iPath Series B Bloomberg Copper Subindex Total Return ETN'>JJC</a>, <a href='https://seekingalpha.com/symbol/CPER' title='United States Copper Index ETF'>CPER</a>, <a href='https://seekingalpha.com/symbol/CUPM' title='iPath Pure Beta Copper ETN'>CUPM</a></li></ul><div class=\"tiny-share-widget\" data-id=\"3277773\" data-linked=\"Zaldivar copper mine workers in Chile approve strike\" data-tweet=\"$GOLD $GOLD $ANFGF - Zaldivar copper mine workers in Chile approve strike https://seekingalpha.com/news/3277773-zaldivar-copper-mine-workers-in-chile-approve-strike?source=tweet\" data-url=\"https://seekingalpha.com/news/3277773-zaldivar-copper-mine-workers-in-chile-approve-strike\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  3:41 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3277764\" data-ts=\"1499713221\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3277764-technology-top-gainers-losers-of-3-00-pm\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Technology - Top Gainers / Losers as of 3:00 pm</a></h4><ul>     <li><b>Gainers:</b> <a href='https://seekingalpha.com/symbol/HCOM' title='Hawaiian Telcom Holdco, Inc.'>HCOM</a> <font color='green'>+19%</font>. <a href='https://seekingalpha.com/symbol/TCCO' title='Technical Communications Corp.'>TCCO</a> <font color='green'>+12%</font>. <a href='https://seekingalpha.com/symbol/MRAM' title='Everspin Technologies'>MRAM</a> <font color='green'>+11%</font>. <a href='https://seekingalpha.com/symbol/SITO' title='SITO Mobile, Ltd.'>SITO</a> <font color='green'>+7%</font>. <a href='https://seekingalpha.com/symbol/MITK' title='Mitek Systems Inc.'>MITK</a> <font color='green'>+7%</font>.</li><li><b>Losers:</b> <a href='https://seekingalpha.com/symbol/MOSY' title='MoSys, Inc.'>MOSY</a> <font color='red'>-10%</font>. FH <font color='red'>-9%</font>. <a href='https://seekingalpha.com/symbol/DGLY' title='Digital Ally, Inc.'>DGLY</a> <font color='red'>-9%</font>. MSDI <font color='red'>-9%</font>. <a href='https://seekingalpha.com/symbol/USAT' title='USA Technologies, Inc.'>USAT</a> <font color='red'>-8%</font>.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3277764\" data-linked=\"Technology - Top Gainers / Losers as of 3:00 pm\" data-tweet=\"$HCOM $TCCO $MRAM - Technology - Top Gainers / Losers as of 3:00 pm https://seekingalpha.com/news/3277764-technology-top-gainers-losers-of-3-00-pm?source=tweet\" data-url=\"https://seekingalpha.com/news/3277764-technology-top-gainers-losers-of-3-00-pm\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  3:00 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>3&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3277765\" data-ts=\"1499713159\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/ERN\" target=\"_blank\">ERN</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3277765-erin-energy-says-planned-new-well-offshore-nigeria-should-double-output\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Erin Energy says planned new well offshore Nigeria should double output</a></h4><ul>     <li>Erin Energy (<a href='https://seekingalpha.com/symbol/ERN' title='Erin Energy Corp.'>ERN</a> <font color='red'>-8.9%</font>) says it is <a href=\"https://seekingalpha.com/pr/16881321-erin-energy-drilling-production-update\" target=\"_blank\">set to start drilling</a> at the Oyo-9 well offshore Nigeria by the end of July, which it expects will double the company's production.</li><li>ERN says Oyo-9 is expected to increase field production by 6K-7K bbl/day of oil; coinciding with the completion of Oyo-9,  ERN says it also will tie back in to its FPSO the Oyo-7 well which could  add an additional 2K bbl/day.</li><li>ERN says rig contractor Pacific Drilling (<a href='https://seekingalpha.com/symbol/PACD' title='Pacific Drilling SA'>PACD</a> <font color='red'>-1.3%</font>) will be ready to mobilize the <em>Pacific Bora</em> drillship for use in the project.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3277765\" data-linked=\"Erin Energy says planned new well offshore Nigeria should double output\" data-tweet=\"$ERN $ERN $PACD - Erin Energy says planned new well offshore Nigeria should double output https://seekingalpha.com/news/3277765-erin-energy-says-planned-new-well-offshore-nigeria-should-double-output?source=tweet\" data-url=\"https://seekingalpha.com/news/3277765-erin-energy-says-planned-new-well-offshore-nigeria-should-double-output\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  2:59 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>1&nbsp;<span class='comments-number'>Comment</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3277768\" data-ts=\"1499713101\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/DRYS\" target=\"_blank\">DRYS</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3277768-dryships-announces-dividend-of-2_5m\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">DryShips announces dividend of $2.5M</a></h4><ul>     <li>DryShips (NASDAQ:<a href='https://seekingalpha.com/symbol/DRYS' title='DryShips Inc.'>DRYS</a>) declared a <a href=\"https://seekingalpha.com/pr/16881625-dryships-inc-announces-dividend-quarter-ended-june-30-2017\" target=\"_blank\">dividend of $2.5M</a> to the holders of the Company's common stock.</li><li>The dividend per share amount to be paid by the Company will be determined based on the number of shares outstanding on the record date.</li>     <li>Payable Aug. 4; for shareholders of record July 20; ex-div July 18.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3277768\" data-linked=\"DryShips announces dividend of $2.5M\" data-tweet=\"$DRYS - DryShips announces dividend of $2.5M https://seekingalpha.com/news/3277768-dryships-announces-dividend-of-2_5m?source=tweet\" data-url=\"https://seekingalpha.com/news/3277768-dryships-announces-dividend-of-2_5m\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  2:58 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>14&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3277756\" data-ts=\"1499710708\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/BBY\" target=\"_blank\">BBY</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3277756-sharp-drop-in-best-buy-seen-overdone\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Sharp drop in Best Buy seen as overdone</a></h4><ul> <li>Shares of Best Buy (NYSE:<a href='https://seekingalpha.com/symbol/BBY' title='Best Buy Co.'>BBY</a>) are <font color='red'>down 6.46%</font> in a strong reaction to news that Amazon is setting up its own version of a Geek Squad.</li> <li>If you think the sell-off is overdone, you're not the only one. Bank of America Merrill Lynch is defending the retailer, saying the new Amazon service will only have a limited impact on Best Buy's sales. Loop Capital notes that Best Buy's Geek Squad has a much broader set of services and thinks it could take years for Amazon to compete at scale. Geek Squad revenue is only 3% of Best Buy's sales, which doesn't square with the large drop in share price today.</li><li>Best Buy is off its lows of the day. Trading voume is 50% higher than normal activity.</li> <li>Source: Bloomberg</li><li>Previously: <a href=\"https://seekingalpha.com/news/3277616-amazon-mobilizes-geek-squad\" target=\"_blank\">Amazon mobilizes its own 'Geek Squad'</a> (July 10)</li> </ul><div class=\"tiny-share-widget\" data-id=\"3277756\" data-linked=\"Sharp drop in Best Buy seen as overdone\" data-tweet=\"$BBY - Sharp drop in Best Buy seen as overdone https://seekingalpha.com/news/3277756-sharp-drop-in-best-buy-seen-overdone?source=tweet\" data-url=\"https://seekingalpha.com/news/3277756-sharp-drop-in-best-buy-seen-overdone\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  2:18 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>6&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3277752\" data-ts=\"1499709696\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3277752-energy-materials-top-gainers-losers-of-2-00-pm\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Energy/Materials - Top Gainers / Losers as of 2:00 pm</a></h4><ul>     <li><b>Gainers:</b> <a href='https://seekingalpha.com/symbol/IPI' title='Intrepid Potash, Inc.'>IPI</a> <font color='green'>+10%</font>. <a href='https://seekingalpha.com/symbol/CLD' title='Cloud Peak Energy, Inc.'>CLD</a> <font color='green'>+9%</font>. <a href='https://seekingalpha.com/symbol/MCEP' title='Mid-Con Energy Partners'>MCEP</a> <font color='green'>+8%</font>. <a href='https://seekingalpha.com/symbol/PES' title='Pioneer Energy Services'>PES</a> <font color='green'>+8%</font>. <a href='https://seekingalpha.com/symbol/UEC' title='Uranium Energy Corp'>UEC</a> <font color='green'>+7%</font>.</li><li><b>Losers:</b> <a href='https://seekingalpha.com/symbol/ZN' title='Zion Oil & Gas Inc'>ZN</a> <font color='red'>-14%</font>. <a href='https://seekingalpha.com/symbol/CIE' title='Cobalt International Energy, Inc.'>CIE</a> <font color='red'>-9%</font>. <a href='https://seekingalpha.com/symbol/ERN' title='Erin Energy Corp.'>ERN</a> <font color='red'>-5%</font>.</li></ul><div class=\"tiny-share-widget\" data-id=\"3277752\" data-linked=\"Energy/Materials - Top Gainers / Losers as of 2:00 pm\" data-tweet=\"$IPI $CLDPQ $MCEP - Energy/Materials - Top Gainers / Losers as of 2:00 pm https://seekingalpha.com/news/3277752-energy-materials-top-gainers-losers-of-2-00-pm?source=tweet\" data-url=\"https://seekingalpha.com/news/3277752-energy-materials-top-gainers-losers-of-2-00-pm\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  2:01 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>2&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3277749\" data-ts=\"1499709140\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/SNVNF\" target=\"_blank\">SNVNF</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3277749-scotiabank-follows-rbc-in-going-neutral-on-sandvine\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Scotiabank follows RBC in going Neutral on Sandvine</a></h4><ul>   <li>Scotiabank has cut its rating on Sandvine (<a href=\"http://seekingalpha.com/symbol/SNVNF\" target=\"_blank\">SNVNF</a> <font color='green'>+4.6%</font>) to Sector Perform, a move that follows the <a href=\"https://seekingalpha.com/news/3276403-rbc-cuts-sandvine-sector-perform\" target=\"_blank\">same cut from RBC</a> in late June.</li>    <li>The bank updated its price target to C$4.40 from C$4.15, implying 2.8% upside from Friday's close. (Shares are <font color='green'>up 4.3%</font> today in Toronto, to C$4.47.)</li>    <li>The shares are still <font color='green'>up 14.3%</font> in Canadian trading since spiking on June 28 following <a href=\"https://seekingalpha.com/news/3276082-sandvine-double-digits-desjardins-boosts-buy\" target=\"_blank\">Desjardin's upgrade to Buy</a>.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3277749\" data-linked=\"Scotiabank follows RBC in going Neutral on Sandvine\" data-tweet=\"$SNVNF - Scotiabank follows RBC in going Neutral on Sandvine https://seekingalpha.com/news/3277749-scotiabank-follows-rbc-in-going-neutral-on-sandvine?source=tweet\" data-url=\"https://seekingalpha.com/news/3277749-scotiabank-follows-rbc-in-going-neutral-on-sandvine\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  1:52 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>2&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3277747\" data-ts=\"1499708522\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/MKSI\" target=\"_blank\">MKSI</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3277747-mks-instrumentsplus-3_8-citi-adds-to-smid-list\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">MKS Instruments +3.8% as Citi adds to SMID list</a></h4><ul>   <li>MKS Instruments (NASDAQ:<a href='https://seekingalpha.com/symbol/MKSI' title='MKS Instruments, Inc.'>MKSI</a>) is <font color='green'>up 3.8%</font> following a move onto Citi's Small/Mid-cap Focus List.</li>    <li>The stock's <font color='red'>tumbled 21%</font> over the past month from a 52-week high, but it's got exposure to the semiconductor capital equipment sector's growth themes, including a 3D NAND shift, the firm says.</li>    <li>Catalysts ahead include the Semicon West show, and its earnings report expected July 26 after the close. (h/t Bloomberg)</li> </ul><div class=\"tiny-share-widget\" data-id=\"3277747\" data-linked=\"MKS Instruments +3.8% as Citi adds to SMID list\" data-tweet=\"$MKSI - MKS Instruments +3.8% as Citi adds to SMID list https://seekingalpha.com/news/3277747-mks-instrumentsplus-3_8-citi-adds-to-smid-list?source=tweet\" data-url=\"https://seekingalpha.com/news/3277747-mks-instrumentsplus-3_8-citi-adds-to-smid-list\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  1:42 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3277746\" data-ts=\"1499707358\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/QURE\" target=\"_blank\">QURE</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3277746-uniqures-hemophilia-b-candidate-amtminus-060-shows-long-term-treatment-benefit-in-mid-stage\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">UniQure&#39;s hemophilia B candidate AMT-060 shows long-term treatment benefit in mid-stage study; shares up 1%</a></h4><ul><li><a href=\"https://seekingalpha.com/pr/16882004-uniqure-announces-updated-long-term-clinical-data-ongoing-phase-ii-trial-amtminus-060\" target=\"_blank\">Long-term follow-up data</a> from a Phase 1/2 clinical trial assessing uniQure's (<a href='https://seekingalpha.com/symbol/QURE' title='uniQure N.V.'>QURE</a> <font color='green'>+0.6%</font>) gene therapy candidate AMT-060 for the treatment of hemophilia B showed a durable effect. The results will be presented today at the ISTH Congress in Berlin.</li><li>The data includes 18 months of follow-up in the low-dose cohort and up to 12 months in the second dose group. All patients have experienced no loss of Factor IX activity and no capsid-specific T-cell activation. No serious adverse events and no development of inhibitors have been observed.</li><li>The annualized spontaneous bleed rate in the second dose cohort was reduced 84% (mean of 0.5 annual bleeds) after gene transfer.</li><li>The company intends to launch a pivotal study to support regulatory submissions as soon as feasible.</li><li>Previously: <a href=\"https://seekingalpha.com/news/3196567-updated-trial-data-show-uniqures-gene-therapy-amtminus-060-induces-sustained-factor-ix\" target=\"_blank\">Updated trial data show uniQure's gene therapy AMT-060 induces sustained Factor IX activity in patients with hemophilia B</a> (July 27, 2016)</li></ul><div class=\"tiny-share-widget\" data-id=\"3277746\" data-linked=\"UniQure&#39;s hemophilia B candidate AMT-060 shows long-term treatment benefit in mid-stage study; shares up 1%\" data-tweet=\"$QURE - UniQure&#39;s hemophilia B candidate AMT-060 shows long-term treatment benefit in mid-stage study; shares up 1% https://seekingalpha.com/news/3277746-uniqures-hemophilia-b-candidate-amtminus-060-shows-long-term-treatment-benefit-in-mid-stage?source=tweet\" data-url=\"https://seekingalpha.com/news/3277746-uniqures-hemophilia-b-candidate-amtminus-060-shows-long-term-treatment-benefit-in-mid-stage\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  1:22 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3277742\" data-ts=\"1499706535\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3277742-financials-top-5-gainers-losers-of-1-00-pm\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Financials - Top 5 Gainers / Losers as of 1:00 PM</a></h4><ul><li><b>Gainers:</b> <a href='https://seekingalpha.com/symbol/MLP' title='Maui Land & Pineapple Company, Inc.'>MLP</a> <font color='green'>+7%</font>. <a href='https://seekingalpha.com/symbol/GCAP' title='GAIN Capital Holdings, Inc.'>GCAP</a> <font color='green'>+6%</font>.<a href='https://seekingalpha.com/symbol/OZM' title='Och-Ziff Capital Management Group LLC'>OZM</a> <font color='green'>+5%</font>. <a href='https://seekingalpha.com/symbol/CG' title='The Carlyle Group'>CG</a> <font color='green'>+5%</font>.</li><li><b>Losers:</b> <a href='https://seekingalpha.com/symbol/RVEN' title='Reven Housing REIT, Inc.'>RVEN</a> <font color='red'>-8%</font>. <a href='https://seekingalpha.com/symbol/PN' title='Patriot National, Inc.'>PN</a> <font color='red'>-5%</font>.</li></ul><div class=\"tiny-share-widget\" data-id=\"3277742\" data-linked=\"Financials - Top 5 Gainers / Losers as of 1:00 PM\" data-tweet=\"$MLP $GCAP $SCU - Financials - Top 5 Gainers / Losers as of 1:00 PM https://seekingalpha.com/news/3277742-financials-top-5-gainers-losers-of-1-00-pm?source=tweet\" data-url=\"https://seekingalpha.com/news/3277742-financials-top-5-gainers-losers-of-1-00-pm\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  1:08 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>2&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3277740\" data-ts=\"1499706011\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/EXEL\" target=\"_blank\">EXEL</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3277740-uks-advisor-to-nhs-backs-inclusion-of-exelixis-cabometyx-for-patients-advanced-kidney-cancer\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">UK&#39;s advisor to NHS backs inclusion of Exelixis&#39; Cabometyx for patients with advanced kidney cancer; shares up 1%</a></h4><ul><li>The UK's National Institute for Health and Care Excellence &#40;NICE&#41;, the advisor to the National Health Service &#40;NHS&#41; on costs and services, <a href=\"https://www.europeanpharmaceuticalreview.com/news/63379/nice-recommends-cabozantinib/\" target=\"_blank\">recommends </a>the option of Exelixis' (<a href='https://seekingalpha.com/symbol/EXEL' title='Exelixis, Inc.'>EXEL</a> <font color='green'>+0.8%</font>) CABOMETYX (cabozantinib) for patients with advanced renal cell carcinoma &#40;RCC&#41;.</li><li>NICE initially failed to back the drug citing the lack of sufficient clinical results supporting the cost/benefit profile. The company submitted additional data to address its concerns.</li><li>Previously: <a href=\"https://seekingalpha.com/news/3208636-exelixis-cabometyx-approved-europe-kidney-cancer-shares-1-percent-premarket\" target=\"_blank\">Exelixis' Cabometyx approved in Europe for kidney cancer; shares up 1% premarket</a> (Sept. 14, 2016)</li></ul><div class=\"tiny-share-widget\" data-id=\"3277740\" data-linked=\"UK&#39;s advisor to NHS backs inclusion of Exelixis&#39; Cabometyx for patients with advanced kidney cancer; shares up 1%\" data-tweet=\"$EXEL - UK&#39;s advisor to NHS backs inclusion of Exelixis&#39; Cabometyx for patients with advanced kidney cancer; shares up 1% https://seekingalpha.com/news/3277740-uks-advisor-to-nhs-backs-inclusion-of-exelixis-cabometyx-for-patients-advanced-kidney-cancer?source=tweet\" data-url=\"https://seekingalpha.com/news/3277740-uks-advisor-to-nhs-backs-inclusion-of-exelixis-cabometyx-for-patients-advanced-kidney-cancer\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  1:00 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>10&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3277738\" data-ts=\"1499705143\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3277738-midday-gainers-losers\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Midday Gainers / Losers</a></h4><ul>     <li><b>Gainers:</b> <a href='https://seekingalpha.com/symbol/MYCC' title='ClubCorp Holdings, Inc.'>MYCC</a> <font color='green'>+30%</font>. <a href='https://seekingalpha.com/symbol/HCOM' title='Hawaiian Telcom Holdco, Inc.'>HCOM</a> <font color='green'>+21%</font>. <a href='https://seekingalpha.com/symbol/CDNA' title='CareDx'>CDNA</a> <font color='green'>+18%</font>. <a href='https://seekingalpha.com/symbol/LILAK' title='Liberty Global, Inc.'>LILAK</a> <font color='green'>+13%</font>. <a href='https://seekingalpha.com/symbol/KOOL' title='Cesca Therapeutics Inc'>KOOL</a> <font color='green'>+12%</font>. <a href='https://seekingalpha.com/symbol/HEBT' title='Hebron Technology Co., Ltd.'>HEBT</a> <font color='green'>+11%</font>. <a href='https://seekingalpha.com/symbol/ABEO' title='Abeona Therapeutics Inc.'>ABEO</a> <font color='green'>+11%</font>. <a href='https://seekingalpha.com/symbol/NNBR' title='NN, Inc.'>NNBR</a> <font color='green'>+9%</font>. <a href='https://seekingalpha.com/symbol/BASI' title='Bioanalytical Systems, Inc.'>BASI</a> <font color='green'>+9%</font>. <a href='https://seekingalpha.com/symbol/IPWR' title='Ideal Power Inc.'>IPWR</a>&nbsp;<font color='green'>+8%.</font></li><li><b>Losers:</b> ITEK <font color='red'>-48%</font>. <a href='https://seekingalpha.com/symbol/ANF' title='Abercrombie & Fitch'>ANF</a> <font color='red'>-21%</font>. <a href='https://seekingalpha.com/symbol/ZN' title='Zion Oil & Gas Inc'>ZN</a> <font color='red'>-17%</font>. <a href='https://seekingalpha.com/symbol/OCUL' title='Ocular Therapeutix'>OCUL</a> <font color='red'>-14%</font>. <a href='https://seekingalpha.com/symbol/DRYS' title='DryShips Inc.'>DRYS</a> <font color='red'>-12%</font>. <a href='https://seekingalpha.com/symbol/NBEV' title='New Age Beverages Corporation'>NBEV</a> <font color='red'>-13%</font>. <a href='https://seekingalpha.com/symbol/LMAT' title='LeMaitre Vascular, Inc.'>LMAT</a> <font color='red'>-13%</font>. <a href='https://seekingalpha.com/symbol/NXTD' title='NXT-ID Inc.'>NXTD</a> <font color='red'>-10%</font>. <a href='https://seekingalpha.com/symbol/DXLG' title='Destination XL Group, Inc.'>DXLG</a> <font color='red'>-10%</font>. <a href='https://seekingalpha.com/symbol/DGLY' title='Digital Ally, Inc.'>DGLY</a> <font color='red'>-10%</font>.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3277738\" data-linked=\"Midday Gainers / Losers\" data-tweet=\"$MYCC $HCOM $CDNA - Midday Gainers / Losers https://seekingalpha.com/news/3277738-midday-gainers-losers?source=tweet\" data-url=\"https://seekingalpha.com/news/3277738-midday-gainers-losers\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 12:45 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>1&nbsp;<span class='comments-number'>Comment</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3277730\" data-ts=\"1499703440\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/NVUS\" target=\"_blank\">NVUS</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3277730-new-finance-chief-novus-shares-ahead-6\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">New finance chief at Novus; shares ahead 6%</a></h4><ul><li>Novus Therapeutics (<a href='https://seekingalpha.com/symbol/NVUS' title='Novus Therapeutics'>NVUS</a> <font color='green'>+5.9%</font>) <a href=\"https://seekingalpha.com/pr/16881174-novus-therapeutics-announces-change-management\" target=\"_blank\">appoints </a>Jon Kuwahara as SVP of Finance and Administration succeeding Christine Ocampo will continue in a consulting role into 2018.</li><li>He joins the firm from Espero Pharmaceuticals where he was VP of Finance.</li></ul><div class=\"tiny-share-widget\" data-id=\"3277730\" data-linked=\"New finance chief at Novus; shares ahead 6%\" data-tweet=\"$NVUS - New finance chief at Novus; shares ahead 6% https://seekingalpha.com/news/3277730-new-finance-chief-novus-shares-ahead-6?source=tweet\" data-url=\"https://seekingalpha.com/news/3277730-new-finance-chief-novus-shares-ahead-6\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 12:17 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3277727\" data-ts=\"1499702422\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3277727-consumer-top-gainers-losers-of-12-00-pm\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Consumer - Top Gainers / Losers as of 12:00 pm</a></h4><ul><li><b>Losers:</b> <a href='https://seekingalpha.com/symbol/NBEV' title='New Age Beverages Corporation'>NBEV</a> <font color='red'>-11%</font>. <a href='https://seekingalpha.com/symbol/LFVN' title='LifeVantage Corporation'>LFVN</a> <font color='red'>-5%</font>.</li></ul><div class=\"tiny-share-widget\" data-id=\"3277727\" data-linked=\"Consumer - Top Gainers / Losers as of 12:00 pm\" data-tweet=\"$NBEV $LFVN - Consumer - Top Gainers / Losers as of 12:00 pm https://seekingalpha.com/news/3277727-consumer-top-gainers-losers-of-12-00-pm?source=tweet\" data-url=\"https://seekingalpha.com/news/3277727-consumer-top-gainers-losers-of-12-00-pm\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 12:00 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>1&nbsp;<span class='comments-number'>Comment</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3277724\" data-ts=\"1499701908\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/TECK\" target=\"_blank\">TECK</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3277724-reuters-india-in-talks-teck-resources-to-buy-coking-coal\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Reuters: India in talks with Teck Resources to buy coking coal</a></h4><ul>     <li>India's government is in talks with Teck Resources (<a href='https://seekingalpha.com/symbol/TECK' title='Teck Resources Limited'>TECK</a> <font color='green'>+3%</font>) for <a href=\"http://www.reuters.com/article/us-india-steel-coal-idUSKBN19T093\" target=\"_blank\">long-term coking coal purchase agreements</a> after a cyclonic disruption in Australia cut supplies earlier this year, Reuters reports.</li>     <li>India's Steel Minister and Steel Authority of India Ltd. executives reportedly were in Canada yesterday for talks with Teck over long-term, formula-based price deals.</li>     <li>SAIL currently meets slightly more than 75% of its needs from BHP Billiton (<a href='https://seekingalpha.com/symbol/BHP' title='BHP Billiton Limited'>BHP</a> <font color='green'>+1.1%</font>), the world's biggest shipper of coking coal, according to the report.</li></ul><div class=\"tiny-share-widget\" data-id=\"3277724\" data-linked=\"Reuters: India in talks with Teck Resources to buy coking coal\" data-tweet=\"$TECK $TECK $BHP - Reuters: India in talks with Teck Resources to buy coking coal https://seekingalpha.com/news/3277724-reuters-india-in-talks-teck-resources-to-buy-coking-coal?source=tweet\" data-url=\"https://seekingalpha.com/news/3277724-reuters-india-in-talks-teck-resources-to-buy-coking-coal\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 11:51 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3277721\" data-ts=\"1499701596\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/LMAT\" target=\"_blank\">LMAT</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3277721-lamaitre-down-13-on-two-downgrades\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">LaMaitre down 13% on two downgrades</a></h4><ul><li>Thinly traded micro cap LaMaitre Vascular (<a href='https://seekingalpha.com/symbol/LMAT' title='LeMaitre Vascular, Inc.'>LMAT</a> <font color='red'>-13.2%</font>) slumps on 50% higher volume on the heels of downgrades to Neutral by Canaccord Genuity and Benchmark, both citing a full valuation.</li><li>Benchmark's Raymond Myers also mentions the sudden departure of the Americas sales chief as a red flag.</li><li>Source: Bloomberg</li></ul><div class=\"tiny-share-widget\" data-id=\"3277721\" data-linked=\"LaMaitre down 13% on two downgrades\" data-tweet=\"$LMAT - LaMaitre down 13% on two downgrades https://seekingalpha.com/news/3277721-lamaitre-down-13-on-two-downgrades?source=tweet\" data-url=\"https://seekingalpha.com/news/3277721-lamaitre-down-13-on-two-downgrades\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 11:46 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3277718\" data-ts=\"1499700439\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/FLIR\" target=\"_blank\">FLIR</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3277718-flir-systemsplus-4-after-two-notch-upgrade-raymond-james\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">FLIR Systems +4% after two-notch upgrade at Raymond James</a></h4><ul><li>FLIR&nbsp;Systems (<a href='https://seekingalpha.com/symbol/FLIR' title='FLIR Systems, Inc.'>FLIR</a> <font color='green'>+3.8%</font>) shoots higher after winning a <a href=\"https://www.streetinsider.com/Analyst+Comments/Raymond+James+Upgrades+FLIR+Systems%2C+Inc.+%28FLIR%29+Two-Notches+to+Strong+Buy/13083349.html\" target=\"_blank\">two-notch upgrade to Strong Buy</a> from Market Perform with a $43 price target from Raymond James, citing the company's new management and an &ldquo;impending up-cycle&rdquo; in defense  spending.</li><li>Ray Jay's Brian Gesuale thinks CEO James Cannon will be a \"positive change agent\" who can take a number  of shareholder friendly actions over the next 6-12  months.</li><li>Gesuale says FLIR's underperformance vs. the market since mid-February was driven by concerns about soft orders and back-end-loaded annual guidance, but the stock's current valuation \"more than adequately\" reflects risks.</li></ul><div class=\"tiny-share-widget\" data-id=\"3277718\" data-linked=\"FLIR Systems +4% after two-notch upgrade at Raymond James\" data-tweet=\"$FLIR - FLIR Systems +4% after two-notch upgrade at Raymond James https://seekingalpha.com/news/3277718-flir-systemsplus-4-after-two-notch-upgrade-raymond-james?source=tweet\" data-url=\"https://seekingalpha.com/news/3277718-flir-systemsplus-4-after-two-notch-upgrade-raymond-james\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 11:27 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>2&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3277717\" data-ts=\"1499700134\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/RHHBY\" target=\"_blank\">RHHBY</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3277717-shire-one-ups-roche-in-hemophilia-battle-prevails-in-germany-legal-spat\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Shire one-ups Roche in hemophilia battle, prevails in Germany legal spat</a></h4><ul><li>A German court enjoins Roche (<a href='https://seekingalpha.com/symbol/RHHBY' title='Roche Holding Ltd ADR'>OTCQX:RHHBY</a> <font color='red'>-0.7%</font>) from making certain promotional statements about the supposed advantages of its hemophilia A med emicizumab compared to Shire's (<a href='https://seekingalpha.com/symbol/SHPG' title='Shire PLC'>SHPG</a> <font color='red'>-3.1%</font>) <a href=\"http://www.feiba.com/hcp/home.html\" target=\"_blank\">FEIBA</a>. &nbsp;Shire accused Roche of making \"incomplete and misleading\" statements about FEIBA-related adverse events in Roche studies, specifically the risk of thromboembolic events. Shire's global chief of its hematology franchise Juliana Dierks accuses Roche of failing to provide adequate data to back up its claim.</li><li>The Hamburg court has jurisdiction since Roche is preparing to present emicizumab data at a medical conference in Berlin this week.</li><li>Roche aims to capture a big slice of the $11B global hemophilia drug market, principally at the expense of current leader Shire. Some analysts believe emicizumab could generate peak sales of $5B.</li><li>Source: <a href=\"http://www.reuters.com/article/us-roche-shire-haemophilia-idUSKBN19V0HX?utm_campaign=trueAnthem:+Trending+Content&amp;utm_content=596397a004d3012766f07978&amp;utm_medium=trueAnthem&amp;utm_source=twitter\" target=\"_blank\">Reuters</a></li></ul><div class=\"tiny-share-widget\" data-id=\"3277717\" data-linked=\"Shire one-ups Roche in hemophilia battle, prevails in Germany legal spat\" data-tweet=\"$RHHBY $RHHBY $SHPG - Shire one-ups Roche in hemophilia battle, prevails in Germany legal spat https://seekingalpha.com/news/3277717-shire-one-ups-roche-in-hemophilia-battle-prevails-in-germany-legal-spat?source=tweet\" data-url=\"https://seekingalpha.com/news/3277717-shire-one-ups-roche-in-hemophilia-battle-prevails-in-germany-legal-spat\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 11:22 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3277689\" data-ts=\"1499698970\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3277689-healthcare-top-5-gainers-losers-of-11-00\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Healthcare - Top 5 Gainers / Losers as of 11:00 am</a></h4><ul>     <li><b>Gainers:</b> <a href='https://seekingalpha.com/symbol/ABEO' title='Abeona Therapeutics Inc.'>ABEO</a> <font color='green'>+13%</font>. <a href='https://seekingalpha.com/symbol/KOOL' title='Cesca Therapeutics Inc'>KOOL</a> <font color='green'>+12%</font>. <a href='https://seekingalpha.com/symbol/AVEO' title='AVEO Pharmaceuticals, Inc.'>AVEO</a> <font color='green'>+10%</font>. APRI <font color='green'>+7%</font>. <a href='https://seekingalpha.com/symbol/SCYX' title='SCYNEXIS, Inc.'>SCYX</a> <font color='green'>+7%</font>.</li><li><b>Losers:</b> ITEK <font color='red'>-51%</font>. <a href='https://seekingalpha.com/symbol/LMAT' title='LeMaitre Vascular, Inc.'>LMAT</a> <font color='red'>-14%</font>. <a href='https://seekingalpha.com/symbol/OCUL' title='Ocular Therapeutix'>OCUL</a> <font color='red'>-9%</font>. <a href='https://seekingalpha.com/symbol/EGLT' title='Egalet Ltd.'>OTC:EGLT</a> <font color='red'>-9%</font>. <a href='https://seekingalpha.com/symbol/CARA' title='Cara Therapeutics Inc.'>CARA</a> <font color='red'>-9%</font>.</li></ul><div class=\"tiny-share-widget\" data-id=\"3277689\" data-linked=\"Healthcare - Top 5 Gainers / Losers as of 11:00 am\" data-tweet=\"$ABEO $THMO $AVEO - Healthcare - Top 5 Gainers / Losers as of 11:00 am https://seekingalpha.com/news/3277689-healthcare-top-5-gainers-losers-of-11-00?source=tweet\" data-url=\"https://seekingalpha.com/news/3277689-healthcare-top-5-gainers-losers-of-11-00\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 11:02 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>1&nbsp;<span class='comments-number'>Comment</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3277704\" data-ts=\"1499698364\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/IMRN\" target=\"_blank\">IMRN</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3277704-immurons-nash-candidate-immminus-124e-fails-to-beat-placebo-in-mid-stage-study-shares-down-8\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Immuron&#39;s NASH candidate IMM-124E fails to beat placebo in mid-stage study; shares down 8%</a></h4><ul><li><a href=\"https://seekingalpha.com/pr/16881478-nash-phase-ii-interim-analysis-reveals-improvement-liver-enzymes-ast-alt-good-safety\" target=\"_blank\">Preliminary results</a> from a 133-subject Phase 2 clinical trial assessing Immuron Limited's (<a href='https://seekingalpha.com/symbol/IMRN' title='Immuron Limited'>IMRN</a> <font color='red'>-7.7%</font>) IMM-124E for the treatment of nonalcoholic steatohepatitis &#40;NASH&#41; failed to demonstrate a statistically valid effect on ALT values compared to placebo. According to the company, the higher dose (1200 mg) showed a positive trend compared to control when certain corrections were made.</li><li>Interim data also failed to show a difference in hepatic fat fraction &#40;HFF&#41; between the cohorts (1200 mg, 600 mg, placebo), the primary endpoint (possibly due to the small sample size).</li><li>Top-line results should be available in Q4.</li></ul><div class=\"tiny-share-widget\" data-id=\"3277704\" data-linked=\"Immuron&#39;s NASH candidate IMM-124E fails to beat placebo in mid-stage study; shares down 8%\" data-tweet=\"$IMRN - Immuron&#39;s NASH candidate IMM-124E fails to beat placebo in mid-stage study; shares down 8% https://seekingalpha.com/news/3277704-immurons-nash-candidate-immminus-124e-fails-to-beat-placebo-in-mid-stage-study-shares-down-8?source=tweet\" data-url=\"https://seekingalpha.com/news/3277704-immurons-nash-candidate-immminus-124e-fails-to-beat-placebo-in-mid-stage-study-shares-down-8\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:52 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>1&nbsp;<span class='comments-number'>Comment</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3277695\" data-ts=\"1499695883\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/SBPH\" target=\"_blank\">SBPH</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3277695-spring-bank-teams-up-gilead-in-clinical-study-of-hepatitis-b-combo-shares-ahead-2\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Spring Bank teams up with Gilead in clinical study of hepatitis B combo; shares ahead 2%</a></h4><ul><li>Spring Bank Pharmaceuticals (<a href='https://seekingalpha.com/symbol/SBPH' title='Spring Bank Pharmaceuticals'>SBPH</a> <font color='green'>+1.7%</font>) announces a second clinical trial <a href=\"https://seekingalpha.com/pr/16881472-spring-bank-announces-collaboration-gilead-hepatitis-b-hbv-phase-2-study-exploring\" target=\"_blank\">collaboration </a>with Gilead Sciences (<a href='https://seekingalpha.com/symbol/GILD' title='Gilead Sciences, Inc.'>GILD</a> <font color='green'>+0.3%</font>) assessing the combination SB 9200 and <a href=\"https://www.vemlidy.com/\" target=\"_blank\">Vemlidy </a>(tenofovir alafenamide) for the treatment of hepatitis B virus &#40;HBV&#41; infection.</li><li>The Phase 2 study will be funded and conducted by Gilead while Spring Bank will supply product.</li><li>SB 9200 is Spring Bank&rsquo;s novel small molecule, orally-available selective immunomodulator compound being developed as both monotherapy and combination therapy as a backbone for the treatment of chronic HBV and other viral diseases.</li><li>Previously: <a href=\"https://seekingalpha.com/news/3212721-arrowhead-spring-bank-team-hepatitis-b\" target=\"_blank\">Arrowhead and Spring Bank team up in hepatitis B</a> (Oct. 6, 2016)</li></ul><div class=\"tiny-share-widget\" data-id=\"3277695\" data-linked=\"Spring Bank teams up with Gilead in clinical study of hepatitis B combo; shares ahead 2%\" data-tweet=\"$SBPH $SBPH $GILD - Spring Bank teams up with Gilead in clinical study of hepatitis B combo; shares ahead 2% https://seekingalpha.com/news/3277695-spring-bank-teams-up-gilead-in-clinical-study-of-hepatitis-b-combo-shares-ahead-2?source=tweet\" data-url=\"https://seekingalpha.com/news/3277695-spring-bank-teams-up-gilead-in-clinical-study-of-hepatitis-b-combo-shares-ahead-2\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:11 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>13&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3277694\" data-ts=\"1499695736\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/ARNC\" target=\"_blank\">ARNC</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3277694-arconicplus-2-j-p-morgan-upgrades-on-valuation\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Arconic +2% as J.P. Morgan upgrades on valuation</a></h4><ul>     <li>Arconic (<a href='https://seekingalpha.com/symbol/ARNC' title='Arconic Inc'>ARNC</a> <font color='green'>+2.1%</font>) opens higher after J.P. Morgan <a href=\"http://www.marketwatch.com/story/arconic-stock-surges-after-jp-morgan-turns-bullish-2017-07-10\" target=\"_blank\">upgrades</a> shares to Overweight from Neutral with a $28 price target, citing improved valuation after the selloff following the Grenfell Tower fire.</li>     <li>\"Grenfell Tower risk hard to assess, but probably manageable and perhaps ultimately zero,\" JPM analyst Seth Seifman writes.</li><li>Despite the recent selloff, ARNC has soared 27% YTD, far outgaining the broader materials sector and the S&amp;P 500.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3277694\" data-linked=\"Arconic +2% as J.P. Morgan upgrades on valuation\" data-tweet=\"$ARNC - Arconic +2% as J.P. Morgan upgrades on valuation https://seekingalpha.com/news/3277694-arconicplus-2-j-p-morgan-upgrades-on-valuation?source=tweet\" data-url=\"https://seekingalpha.com/news/3277694-arconicplus-2-j-p-morgan-upgrades-on-valuation\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:08 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>9&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3277687\" data-ts=\"1499694975\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/RCKT\" target=\"_blank\">RCKT</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3277687-inoteks-trabodenoson-flop-sinks-shares-down-45\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Inotek&#39;s trabodenoson flop sinks shares, down 45%</a></h4><ul><li>Nano cap Inotek Pharmaceuticals (ITEK <font color='red'>-44.9%</font>) craters on double normal volume after it <a href=\"https://seekingalpha.com/pr/16880878-inotek-pharmaceuticals-announces-top-line-results-phase-2-fixed-dose-combination-trial\" target=\"_blank\">reported </a>results from a Phase 2 study that failed to demonstrate a significant treatment benefit for glaucoma candidate trabodenoson.</li><li>Previously: <a href=\"https://seekingalpha.com/news/3277558-inotek-glaucoma-drug-showed-clinical-advantage-phase-2-trial\" target=\"_blank\">Inotek glaucoma drug showed no clinical advantage in Phase 2 trial</a> (July 7)</li></ul><div class=\"tiny-share-widget\" data-id=\"3277687\" data-linked=\"Inotek&#39;s trabodenoson flop sinks shares, down 45%\" data-tweet=\"$RCKT - Inotek&#39;s trabodenoson flop sinks shares, down 45% https://seekingalpha.com/news/3277687-inoteks-trabodenoson-flop-sinks-shares-down-45?source=tweet\" data-url=\"https://seekingalpha.com/news/3277687-inoteks-trabodenoson-flop-sinks-shares-down-45\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:56 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3277683\" data-ts=\"1499694273\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/KBH\" target=\"_blank\">KBH</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3277683-kb-home-and-pulte-downgraded-to-underperform-on-fancy-valuations\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">KB Home and Pulte downgraded to Underperform on fancy valuations</a></h4><ul><li>Big runs for both names this year - KB Home (NYSE:<a href='https://seekingalpha.com/symbol/KBH' title='KB Home'>KBH</a>) is&nbsp;<font color='green'>up 51%</font>&nbsp;and PulteGroup (NYSE:<a href='https://seekingalpha.com/symbol/PHM' title='PulteGroup, Inc.'>PHM</a>)&nbsp;<font color='green'>35%</font>&nbsp;- have left the stocks with unjustified valuations, says analyst&nbsp;Haendel St. Juste downgrading to Underperform.</li><li>While KB Home has been able to show significantly improved gross margins, says St. Juste, &nbsp;H2 new home order comps are likely to be very difficult.</li><li>As for Pulte, it's selling for more than 2x tangible book value - the sort of multiple only warranted during \"extremely unique circumstances.\"</li><li>KBH&nbsp;<font color='red'>-0.7%</font>, PHM&nbsp;<font color='red'>-0.15%</font>&nbsp;on today's session.</li></ul><div class=\"tiny-share-widget\" data-id=\"3277683\" data-linked=\"KB Home and Pulte downgraded to Underperform on fancy valuations\" data-tweet=\"$KBH $KBH $PHM - KB Home and Pulte downgraded to Underperform on fancy valuations https://seekingalpha.com/news/3277683-kb-home-and-pulte-downgraded-to-underperform-on-fancy-valuations?source=tweet\" data-url=\"https://seekingalpha.com/news/3277683-kb-home-and-pulte-downgraded-to-underperform-on-fancy-valuations\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:44 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3277677\" data-ts=\"1499693336\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/JNPR\" target=\"_blank\">JNPR</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3277677-juniper-networksplus-1_5-bmo-boosts-to-buy\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Juniper Networks +1.5% as BMO boosts to Buy</a></h4><ul>   <li>Juniper Networks (NYSE:<a href='https://seekingalpha.com/symbol/JNPR' title='Juniper Networks'>JNPR</a>) is <font color='green'>up 1.5%</font> premarket after an upgrade to Buy at BMO, which sees some sustainable strength in the company's switching business.</li>    <li>Low expectations in its routing and security areas represent a \"call option\" on the shares, says analyst Tim Long, with the company seeing upside in spine/core switching with its QFX10000 high-performance switches.</li>    <li>He's boosted the firm's price target to $34 from $31, implying 19.5% upside.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3277677\" data-linked=\"Juniper Networks +1.5% as BMO boosts to Buy\" data-tweet=\"$JNPR - Juniper Networks +1.5% as BMO boosts to Buy https://seekingalpha.com/news/3277677-juniper-networksplus-1_5-bmo-boosts-to-buy?source=tweet\" data-url=\"https://seekingalpha.com/news/3277677-juniper-networksplus-1_5-bmo-boosts-to-buy\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:28 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3277675\" data-ts=\"1499693218\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/ROKA\" target=\"_blank\">ROKA</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3277675-roka-bio-to-market-pure-bios-antimicrobial-line-to-food-industry-shares-ahead-8-premarket\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Roka Bio to market PURE Bio&#39;s antimicrobial line to food industry; shares ahead 8% premarket</a></h4><ul><li>Thinly traded nano cap Roka Bioscience (NASDAQ:<a href='https://seekingalpha.com/symbol/ROKA' title='Roka Bioscience'>ROKA</a>) is up<font color='green'> 8%</font>&nbsp;premarket on light volume in response to the news that it has inked a two-year nonexclusive <a href=\"https://seekingalpha.com/pr/16881506-pure-bioscience-announces-co-marketing-supply-agreement-roka-bioscience-inc\" target=\"_blank\">agreement </a>with PURE Bioscience (<a href='https://seekingalpha.com/symbol/PURE' title='PURE Bioscience'>OTC:PURE</a>) to market its line of antimicrobial disinfecting and sanitizing products and processing aids to the food industry, expanding its reach in the space.</li><li>Financial terms are not disclosed.</li></ul><div class=\"tiny-share-widget\" data-id=\"3277675\" data-linked=\"Roka Bio to market PURE Bio&#39;s antimicrobial line to food industry; shares ahead 8% premarket\" data-tweet=\"$ROKA $ROKA $PURE - Roka Bio to market PURE Bio&#39;s antimicrobial line to food industry; shares ahead 8% premarket https://seekingalpha.com/news/3277675-roka-bio-to-market-pure-bios-antimicrobial-line-to-food-industry-shares-ahead-8-premarket?source=tweet\" data-url=\"https://seekingalpha.com/news/3277675-roka-bio-to-market-pure-bios-antimicrobial-line-to-food-industry-shares-ahead-8-premarket\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:26 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3277673\" data-ts=\"1499692873\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/AVEO\" target=\"_blank\">AVEO</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3277673-aveo-set-to-continue-up-move-on-looming-eu-approval-of-tivozanib-for-kidney-cancer-shares\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">AVEO set to continue up move on looming EU approval of tivozanib for kidney cancer; shares ahead 12% premarket</a></h4><ul><li>AVEO Pharmaceuticals (NASDAQ:<a href='https://seekingalpha.com/symbol/AVEO' title='AVEO Pharmaceuticals, Inc.'>AVEO</a>) is up&nbsp;<font color='green'>12%&nbsp;</font>premarket on robust volume, signaling a continuation of the rally that began on June 23 after the European Medicines Agency's Committee for Medicinal Products for Human Use &#40;CHMP&#41; <a href=\"https://www.streetinsider.com/Analyst+Comments/AVEO+Oncology+%28AVEO%29%3A+Buy+Ahead+Of+TIVO-3+Futility+Analysis+-+FBR/13061338.html\" target=\"_blank\">backed approval</a> of tivozanib for the first-line treatment of renal cell carcinoma. Shares are up almost four-fold since then.</li><li>Previously: <a href=\"https://seekingalpha.com/news/2997176-aveo-inks-license-deal-tivozanib-europe-kidney-cancer-shares-31-percent\" target=\"_blank\">AVEO inks license deal for tivozanib in Europe for kidney cancer; shares up 31%</a> (Dec. 21, 2015)</li></ul><div class=\"tiny-share-widget\" data-id=\"3277673\" data-linked=\"AVEO set to continue up move on looming EU approval of tivozanib for kidney cancer; shares ahead 12% premarket\" data-tweet=\"$AVEO - AVEO set to continue up move on looming EU approval of tivozanib for kidney cancer; shares ahead 12% premarket https://seekingalpha.com/news/3277673-aveo-set-to-continue-up-move-on-looming-eu-approval-of-tivozanib-for-kidney-cancer-shares?source=tweet\" data-url=\"https://seekingalpha.com/news/3277673-aveo-set-to-continue-up-move-on-looming-eu-approval-of-tivozanib-for-kidney-cancer-shares\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:21 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>10&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3277672\" data-ts=\"1499692791\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/CETV\" target=\"_blank\">CETV</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3277672-cetvplus-6_2-on-deal-to-sell-croatian-slovenian-operations\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">CETV +6.2% on deal to sell Croatian, Slovenian operations</a></h4><ul>   <li>Central European Media (NASDAQ:<a href='https://seekingalpha.com/symbol/CETV' title='Central European Media Enterprises Ltd.'>CETV</a>) is <font color='green'>up 6.2%</font> premarket after word that it will <a href=\"https://seekingalpha.com/pr/16881078-central-european-media-enterprises-announces-divestiture-assets-accelerate-deleveraging\" target=\"_blank\">sell its broadcast operations in Croatia and in Slovenia</a> for &euro;230M (about $262.5M).</li>    <li>The company is selling Nova TV in Croatia and POP TV in Slovenia to Slovenia Broadband. Combined OIBDA for the two operations over the 12 months ended March 31 was $13.8M.</li>    <li>It will use proceeds to prepay a &euro;250.8M term loan coming due next year, cutting leverage and reducing average borrowing cost by 275 basis points (to 4.5%).</li>    <li>The company says it will be accretive to margin as well, since interest savings of $30M annually offset the cash generated by the two operations.</li>    <li>The deal is set to close by year's end.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3277672\" data-linked=\"CETV +6.2% on deal to sell Croatian, Slovenian operations\" data-tweet=\"$CETV - CETV +6.2% on deal to sell Croatian, Slovenian operations https://seekingalpha.com/news/3277672-cetvplus-6_2-on-deal-to-sell-croatian-slovenian-operations?source=tweet\" data-url=\"https://seekingalpha.com/news/3277672-cetvplus-6_2-on-deal-to-sell-croatian-slovenian-operations\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:19 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3277669\" data-ts=\"1499692480\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3277669-premarket-gainers-of-9-05\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Premarket Gainers as of 9:05 am</a></h4><ul><li><a href='https://seekingalpha.com/symbol/MYCC' title='ClubCorp Holdings, Inc.'>MYCC</a>&nbsp;<font color='green'>+30%</font>&nbsp;on being <a href=\"https://seekingalpha.com/news/3277623-apollo-global-buy-clubcorp-1_1b\" target=\"_blank\">acquired</a> by Apollo Global (NYSE:<a href='https://seekingalpha.com/symbol/APO' title='Apollo Global Management, LLC'>APO</a>).</li><li>MSDI <font color='green'>+18%</font>.</li><li><a href='https://seekingalpha.com/symbol/KOOL' title='Cesca Therapeutics Inc'>KOOL</a> <font color='green'>+12%</font>&nbsp;on <a href=\"https://seekingalpha.com/pr/16881280-cesca-therapeutics-acquires-cell-processing-systems-syngen-asset-acquisition-agreement\" target=\"_blank\">acquiring</a> the cell processing system of SynGen under asset acquisition agreement.</li><li><a href='https://seekingalpha.com/symbol/AVEO' title='AVEO Pharmaceuticals, Inc.'>AVEO</a> <font color='green'>+11%</font>.</li></ul><div class=\"tiny-share-widget\" data-id=\"3277669\" data-linked=\"Premarket Gainers as of 9:05 am\" data-tweet=\"$MYCC $APO $INNT - Premarket Gainers as of 9:05 am https://seekingalpha.com/news/3277669-premarket-gainers-of-9-05?source=tweet\" data-url=\"https://seekingalpha.com/news/3277669-premarket-gainers-of-9-05\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:14 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3277668\" data-ts=\"1499692433\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3277668-premarket-losers-of-9-05\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Premarket Losers as of 9:05 am</a></h4><ul>     <li>ITEK <font color='red'>-45%</font>.</li><li><a href='https://seekingalpha.com/symbol/ANF' title='Abercrombie & Fitch'>ANF</a>&nbsp;<font color='red'>-13%</font>&nbsp;on stalled <a href=\"https://seekingalpha.com/news/3277646-abercrombie-and-fitch-dives-wsj-report-stalled-deal-talks\" target=\"_blank\">deal</a> talks.</li><li><a href='https://seekingalpha.com/symbol/OCUL' title='Ocular Therapeutix'>OCUL</a>&nbsp;<font color='red'>-9%</font>.</li><li><a href='https://seekingalpha.com/symbol/DRYS' title='DryShips Inc.'>DRYS</a> <font color='red'>-7%</font>.</li>  </ul><div class=\"tiny-share-widget\" data-id=\"3277668\" data-linked=\"Premarket Losers as of 9:05 am\" data-tweet=\"$RCKT $ANF $OCUL - Premarket Losers as of 9:05 am https://seekingalpha.com/news/3277668-premarket-losers-of-9-05?source=tweet\" data-url=\"https://seekingalpha.com/news/3277668-premarket-losers-of-9-05\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:13 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3277663\" data-ts=\"1499691541\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/LUV\" target=\"_blank\">LUV</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3277663-southwest-airlines-dips-after-underwhelming-unit-revenue-update\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Southwest Airlines dips after underwhelming unit revenue update</a></h4><ul> <li>Southwest Airlines (NYSE:<a href='https://seekingalpha.com/symbol/LUV' title='Southwest Airlines Co.'>LUV</a>) is lower after its traffic report and Q2 unit revenue guidance underwhelms.</li> <li>UBS advises that the carrier's underperformance\" was \"rare\" and is unclear what drove it (per <a href=\"https://twitter.com/thenotablecalls\" target=\"_blank\">@NotableCalls</a>).</li><li>Previously: <a href=\"https://seekingalpha.com/news/3277621-southwest-airlines-backs-q2-unit-revenue-guidance\" target=\"_blank\">Southwest Airlines backs Q2 unit revenue guidance</a> (July 10)</li> <li>LUV <font color='red'>-1.93%</font> premarket to $63.00.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3277663\" data-linked=\"Southwest Airlines dips after underwhelming unit revenue update\" data-tweet=\"$LUV - Southwest Airlines dips after underwhelming unit revenue update https://seekingalpha.com/news/3277663-southwest-airlines-dips-after-underwhelming-unit-revenue-update?source=tweet\" data-url=\"https://seekingalpha.com/news/3277663-southwest-airlines-dips-after-underwhelming-unit-revenue-update\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  8:59 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>1&nbsp;<span class='comments-number'>Comment</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3277657\" data-ts=\"1499691021\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/OCUL\" target=\"_blank\">OCUL</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3277657-ocular-therapeutix-poised-to-continue-slide-shares-off-5-premarket\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Ocular Therapeutix poised to continue slide, shares off 5% premarket</a></h4><ul><li>Ocular Therapeutix (NASDAQ:<a href='https://seekingalpha.com/symbol/OCUL' title='Ocular Therapeutix'>OCUL</a>) is down<font color='red'> 5%</font>&nbsp;premarket on average volume, potentially adding to its 30% drop since last Thursday when STAT News' Adam Feuerstein <a href=\"https://www.statnews.com/2017/07/06/ocular-therapeutix-fda-contamination/\" target=\"_blank\">reported </a>that quality issues could trip up FDA approval of eye med DEXTENZA (dexamethasone insert).</li><li>Previously: <a href=\"https://seekingalpha.com/news/3236670-ocular-resubmits-u-s-marketing-application-dextenza\" target=\"_blank\">Ocular resubmits U.S. marketing application for Dextenza</a> (Jan. 23)</li></ul><div class=\"tiny-share-widget\" data-id=\"3277657\" data-linked=\"Ocular Therapeutix poised to continue slide, shares off 5% premarket\" data-tweet=\"$OCUL - Ocular Therapeutix poised to continue slide, shares off 5% premarket https://seekingalpha.com/news/3277657-ocular-therapeutix-poised-to-continue-slide-shares-off-5-premarket?source=tweet\" data-url=\"https://seekingalpha.com/news/3277657-ocular-therapeutix-poised-to-continue-slide-shares-off-5-premarket\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  8:50 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>11&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3277654\" data-ts=\"1499690696\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/HCOM\" target=\"_blank\">HCOM</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3277654-cincinnati-bell-buys-hawaiian-telecom-for-30_75-share\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Cincinnati Bell buys Hawaiian Telecom for $30.75/share</a></h4><ul><li>Hawaiian Telecom (NASDAQ:<a href='https://seekingalpha.com/symbol/HCOM' title='Hawaiian Telcom Holdco, Inc.'>HCOM</a>) <font color='green'>+15.8%</font> premarket after Cincinnati Bell (NYSE:<a href='https://seekingalpha.com/symbol/CBB' title='Cincinnati Bell Inc.'>CBB</a>) <a href=\"https://seekingalpha.com/pr/16881249-hawaiian-telcom-enters-definitive-agreement-merge-cincinnati-bell\" target=\"_blank\">agrees to acquire</a> the company for ~$650M, including debt.</li><li>The $30.75/share offer represents a 26% premium to HCOM's Friday closing price; the deal allows HCOM shareholders  a choice of cash, stock or a combination.</li><li>Separately, CBB also says it is <a href=\"https://seekingalpha.com/pr/16881215-cincinnati-bell-inc-combine-hawaiian-telcom-onx-enterprise-solutions\" target=\"_blank\">buying</a> technology  services provider OnX Enterprise Solutions for $201M.</li></ul><div class=\"tiny-share-widget\" data-id=\"3277654\" data-linked=\"Cincinnati Bell buys Hawaiian Telecom for $30.75/share\" data-tweet=\"$HCOM $HCOM $CBB - Cincinnati Bell buys Hawaiian Telecom for $30.75/share https://seekingalpha.com/news/3277654-cincinnati-bell-buys-hawaiian-telecom-for-30_75-share?source=tweet\" data-url=\"https://seekingalpha.com/news/3277654-cincinnati-bell-buys-hawaiian-telecom-for-30_75-share\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  8:44 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3277649\" data-ts=\"1499689580\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/ANF\" target=\"_blank\">ANF</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3277649-no-buyout-deal-for-abercrombie-fitch\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">No buyout deal for Abercrombie &amp; Fitch</a></h4><ul> <li>Abercrombie &amp; Fitch (NYSE:<a href='https://seekingalpha.com/symbol/ANF' title='Abercrombie & Fitch'>ANF</a>) posts a statement ahead of a WSJ story on stalled deal talks.</li> <li>\"After a comprehensive review of all relevant factors, with the assistance of our financial advisor, the A&amp;F Board of Directors determined that the best path to enhance value for stockholders is the rigorous execution of our business plan.\"</li> <li>\"We believe in the prospects for our business and the opportunities for our brands. We are generating solid comp store sales momentum at Hollister and continue to refine and implement strategies to position the Abercrombie brand for revitalized performance.\"</li><li>Previously: <a href=\"https://seekingalpha.com/news/3277646-abercrombie-and-fitch-dives-wsj-report-stalled-deal-talks\" target=\"_blank\">Abercrombie &amp; Fitch dives on WSJ report of stalled deal talks</a> (July 10)</li> <li>ANF&nbsp;<font color='red'>-14.80%</font>&nbsp;premarket to $10.36.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3277649\" data-linked=\"No buyout deal for Abercrombie &amp; Fitch\" data-tweet=\"$ANF - No buyout deal for Abercrombie &amp; Fitch https://seekingalpha.com/news/3277649-no-buyout-deal-for-abercrombie-fitch?source=tweet\" data-url=\"https://seekingalpha.com/news/3277649-no-buyout-deal-for-abercrombie-fitch\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  8:26 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3277646\" data-ts=\"1499689269\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/ANF\" target=\"_blank\">ANF</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3277646-abercrombie-fitch-dives-on-wsj-report-of-stalled-deal-talks\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Abercrombie &amp; Fitch dives on WSJ report of stalled deal talks</a></h4><ul> <li>Abercrombie &amp; Fitch (NYSE:<a href='https://seekingalpha.com/symbol/ANF' title='Abercrombie & Fitch'>ANF</a>) <font color='red'>slides 16%</font> in premarket trading after <em>Wall Street Journa</em>l reporter Dana Mattiolo <a href=\"https://twitter.com/DanaMattioli/status/884383498106175488\" target=\"_blank\">tweets</a> that deal talks have stalled with potential bidders.</li> <li>The full <em>WSJ</em> story is expected to be posted shortly.</li>  </ul><div class=\"tiny-share-widget\" data-id=\"3277646\" data-linked=\"Abercrombie &amp; Fitch dives on WSJ report of stalled deal talks\" data-tweet=\"$ANF - Abercrombie &amp; Fitch dives on WSJ report of stalled deal talks https://seekingalpha.com/news/3277646-abercrombie-fitch-dives-on-wsj-report-of-stalled-deal-talks?source=tweet\" data-url=\"https://seekingalpha.com/news/3277646-abercrombie-fitch-dives-on-wsj-report-of-stalled-deal-talks\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  8:21 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3277637\" data-ts=\"1499688651\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/BHC\" target=\"_blank\">BHC</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3277637-valeant-pays-down-811m-of-senior-secured-term-loans\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Valeant pays down $811M of senior secured term loans</a></h4><ul> <li>Valeant Pharmaceuticals (VRX) <a href=\"https://seekingalpha.com/pr/16881216-valeant-pays-811-million-senior-secured-term-loans\" target=\"_blank\">announces</a> that the Company has used the net proceeds from the sale&nbsp;of Dendreon Pharmaceuticals LLC&nbsp;to pay down $811M of its senior secured term loans.</li> <li>With this transaction, all mandatory amortization has been paid through 2019 thereby reducing its debt by more than $4.3B since the end of Q12016.</li><li>Shares are up&nbsp;<font color='green'>2%</font>&nbsp;premarket on light volume.</li>   </ul><div class=\"tiny-share-widget\" data-id=\"3277637\" data-linked=\"Valeant pays down $811M of senior secured term loans\" data-tweet=\"$BHC - Valeant pays down $811M of senior secured term loans https://seekingalpha.com/news/3277637-valeant-pays-down-811m-of-senior-secured-term-loans?source=tweet\" data-url=\"https://seekingalpha.com/news/3277637-valeant-pays-down-811m-of-senior-secured-term-loans\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  8:10 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>153&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3277627\" data-ts=\"1499687899\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/CLLS\" target=\"_blank\">CLLS</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3277627-cellectis-calyxt-announces-proposed-ipo-of-100m\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Cellectis: Calyxt announces proposed IPO of $100M</a></h4><ul> <li>Cellectis S.A. (NASDAQ:<a href='https://seekingalpha.com/symbol/CLLS' title='Cellectis S.A.'>CLLS</a>) and <a href=\"http://www.calyxt.com/\" target=\"_blank\">Calyxt</a> <a href=\"https://seekingalpha.com/pr/16881246-cellectis-calyxt-announces-proposed-initial-public-offering-100_0-million\" target=\"_blank\">announces</a> that Calyxt has commenced a proposed initial public offering &#40;IPO&#41; of       6.06M shares of Calyxt&rsquo;s common stock with the SEC.</li><li>The estimated price range for the IPO is $15.00 to $18.00 yielding in gross proceeds of $100M. Underwriters will be granted an option to purchase 909,091 additional shares to cover over-allotment.</li><li>The common stock will be listed under the ticker symbol &ldquo;CLXT.&rdquo;</li><li><strong>Update</strong>: Shares are up&nbsp;<font color='green'>6%</font>&nbsp;premarket on light volume.</li>          </ul><div class=\"tiny-share-widget\" data-id=\"3277627\" data-linked=\"Cellectis: Calyxt announces proposed IPO of $100M\" data-tweet=\"$CLLS - Cellectis: Calyxt announces proposed IPO of $100M https://seekingalpha.com/news/3277627-cellectis-calyxt-announces-proposed-ipo-of-100m?source=tweet\" data-url=\"https://seekingalpha.com/news/3277627-cellectis-calyxt-announces-proposed-ipo-of-100m\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  7:58 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>7&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3277631\" data-ts=\"1499686594\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/PYPL\" target=\"_blank\">PYPL</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3277631-paypal-higher-after-favorable-analyst-coverage\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">PayPal higher after favorable analyst coverage</a></h4><ul> <li>PayPal (NASDAQ:<a href='https://seekingalpha.com/symbol/PYPL' title='PayPal Holdings, Inc.'>PYPL</a>) is higher in early action after some favorable ratings moves by investment firms.</li> <li>Bernstein boosts its rating on PayPal to Outperform from Market Perform and assigns a price target of $61.</li> <li>KeyBanc launches coverage on the digital payments stock at Overweight, with a $60 PT.</li> <li>Shares of PayPal are <font color='green'>up 1.45%</font> to $54.75 vs. a 52-week trading range of $36.28 to $55.14.</li></ul><div class=\"tiny-share-widget\" data-id=\"3277631\" data-linked=\"PayPal higher after favorable analyst coverage\" data-tweet=\"$PYPL - PayPal higher after favorable analyst coverage https://seekingalpha.com/news/3277631-paypal-higher-after-favorable-analyst-coverage?source=tweet\" data-url=\"https://seekingalpha.com/news/3277631-paypal-higher-after-favorable-analyst-coverage\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  7:36 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>4&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3277623\" data-ts=\"1499685075\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/MYCC\" target=\"_blank\">MYCC</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3277623-apollo-global-to-buy-clubcorp-for-1_1b\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Apollo Global to buy ClubCorp for $1.1B</a></h4><ul>     <li>ClubCorp (NYSE:<a href='https://seekingalpha.com/symbol/MYCC' title='ClubCorp Holdings, Inc.'>MYCC</a>) <font color='green'>+29.7%</font> premarket after Apollo Global Management (NYSE:<a href='https://seekingalpha.com/symbol/APO' title='Apollo Global Management, LLC'>APO</a>) announced yesterday it had <a href=\"https://seekingalpha.com/pr/16881052-clubcorp-enters-definitive-agreement-acquired-certain-investment-funds-affiliated-apollo\" target=\"_blank\">agreed to acquire</a> the golf and country club operator for ~$1.1B.</li>     <li>APO said it will pay $17.12/share in cash for MYCC, a 30.7% premium over Friday's closing price.</li>     <li>MYCC also declared a one-time dividend of $0.13/share to be paid later this month.</li></ul><div class=\"tiny-share-widget\" data-id=\"3277623\" data-linked=\"Apollo Global to buy ClubCorp for $1.1B\" data-tweet=\"$MYCC $MYCC $APO - Apollo Global to buy ClubCorp for $1.1B https://seekingalpha.com/news/3277623-apollo-global-to-buy-clubcorp-for-1_1b?source=tweet\" data-url=\"https://seekingalpha.com/news/3277623-apollo-global-to-buy-clubcorp-for-1_1b\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  7:11 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>10&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3277621\" data-ts=\"1499684932\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/LUV\" target=\"_blank\">LUV</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3277621-southwest-airlines-backs-q2-unit-revenue-guidance\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Southwest Airlines backs Q2 unit revenue guidance</a></h4><ul>     <li>Southwest Airlines (NYSE:<a href='https://seekingalpha.com/symbol/LUV' title='Southwest Airlines Co.'>LUV</a>) <a href=\"https://seekingalpha.com/pr/16881178-southwest-airlines-reports-june-traffic\" target=\"_blank\">reports</a> revenue passenger miles 3.7% in June to 11.919B.</li>     <li>Capacity was up 3.8% to 13.643B available seat miles.</li>     <li>June load factor was flat Y/Y at 87.4%. YTD load factor -30 bps to 82.9%.</li>     <li>Southwest sticks with guidance for a 1% to 2% increase in Q2 operating revenue per available seat mile.</li><li>LUV&nbsp;<font color='red'>-0.40%</font>&nbsp;premarket to $63.98.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3277621\" data-linked=\"Southwest Airlines backs Q2 unit revenue guidance\" data-tweet=\"$LUV - Southwest Airlines backs Q2 unit revenue guidance https://seekingalpha.com/news/3277621-southwest-airlines-backs-q2-unit-revenue-guidance?source=tweet\" data-url=\"https://seekingalpha.com/news/3277621-southwest-airlines-backs-q2-unit-revenue-guidance\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  7:08 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3277620\" data-ts=\"1499684901\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/PNTR\" target=\"_blank\">PNTR</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3277620-pointer-telocations-strong-run-continues-after-positive-coverage\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Pointer Telocation&#39;s strong run continues after positive coverage</a></h4><ul><li>Roth Capital Partners' William Gibson late last week <a href=\"https://www.streetinsider.com/New+Coverage/Roth+Capital+Starts+Pointer+Telocation+%28PNTR%29+at+Buy/13079183.html\" target=\"_blank\">initiated coverage</a> with a Buy rating and $16 price target, suggesting&nbsp;<font color='green'>nearly 40% upside</font>.</li><li>\"We expect growth to continue, producing incrementally higher operating margins as MRM (mobile resource management) service revenue grows,\" says Gibson. He sees 2017 earnings of $5.6M, or $0.70 per share, and 2018 of $6.5M, or $0.80.</li><li>Pointer (NASDAQ:<a href='https://seekingalpha.com/symbol/PNTR' title='Pointer Telocation Ltd.'>PNTR</a>)&nbsp;<font color='green'>gained 1.3%</font>&nbsp;Friday following the Roth note, and is now&nbsp;<font color='green'>higher by 71.%</font>&nbsp;YTD.</li><li>See important&nbsp;<a href=\"https://seekingalpha.com/page/corporate-visibility-program\" target=\"_blank\">disclosures</a>.</li></ul><div class=\"tiny-share-widget\" data-id=\"3277620\" data-linked=\"Pointer Telocation&#39;s strong run continues after positive coverage\" data-tweet=\"$PNTR - Pointer Telocation&#39;s strong run continues after positive coverage https://seekingalpha.com/news/3277620-pointer-telocations-strong-run-continues-after-positive-coverage?source=tweet\" data-url=\"https://seekingalpha.com/news/3277620-pointer-telocations-strong-run-continues-after-positive-coverage\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  7:08 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>2&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3277606\" data-ts=\"1499676579\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/KHC\" target=\"_blank\">KHC</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3277606-kraft-heinz-seen-making-hostile-play-for-unilever\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Kraft Heinz seen making hostile play for Unilever</a></h4><ul> <li>Susquehanna's Pablo Zuanic sets the odds at more than 75% that Kraft Heinz (NASDAQ:<a href='https://seekingalpha.com/symbol/KHC' title='The Kraft Heinz Company'>KHC</a>) makes a hostile bid for Unilever (<a href='https://seekingalpha.com/symbol/UN' title='Unilever NV'>UN</a>, <a href='https://seekingalpha.com/symbol/UL' title='Unilever Plc'>UL</a>).</li> <li>The analyst says it's \"telling\" that Kraft hasn't pulled any M&amp;A triggers since being rebuffed by Unilever and notes the company is still a good fit. Influential Kraft investor Warren Buffett is expected to come around on Kraft paying out as much as $200B in the consumer packaged goods mega-merger scenario.</li> <li>Shares of Unilever are <font color='green'>up 1.66%</font> in premarket action.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3277606\" data-linked=\"Kraft Heinz seen making hostile play for Unilever\" data-tweet=\"$KHC $KHC $UN - Kraft Heinz seen making hostile play for Unilever https://seekingalpha.com/news/3277606-kraft-heinz-seen-making-hostile-play-for-unilever?source=tweet\" data-url=\"https://seekingalpha.com/news/3277606-kraft-heinz-seen-making-hostile-play-for-unilever\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  4:49 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>36&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3277604\" data-ts=\"1499676208\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3277604-global-markets-edge-higher\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Global markets edge higher</a></h4><ul>     <li>The Shanghai Composite in China closed the day <font color='red'>0.2% lower</font>, while the Nikkei in Japan was <font color='green'>up 0.8%</font>. European stocks are edging higher, with the Stoxx 600 <font color='green'>up 0.3%</font> as bank stocks lead the way.</li><li>The dollar <font color='green'>rose almost 0.4%</font> to &yen;114.30 to mark a two-month high before falling back to &yen;114.20.</li><li>Crude oil prices are slightly lower to extend on the 3% drop in the last session. WTI crude oil futures&nbsp;<font color='red'>-0.11%</font>&nbsp;to $44.18/bbl at last check. Brent crude <font color='red'>-0.13%</font> to $46.65/bbl.</li><li>U.S. stock futures are pointing to gains at the open.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3277604\" data-linked=\"Global markets edge higher\" data-tweet=\"Global markets edge higher https://seekingalpha.com/news/3277604-global-markets-edge-higher?source=tweet\" data-url=\"https://seekingalpha.com/news/3277604-global-markets-edge-higher\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  4:43 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>1&nbsp;<span class='comments-number'>Comment</span></span></span></div></div></li>","count":57,"message":null,"success":true,"today":{"start":1577077200,"end":1577163599,"str":"Monday, December 23, 2019"},"yesterday":{"start":1576990800,"end":1577077199}}